Table 2.
Physical characteristics of radiopharmaceuticals used for bone pain palliation
| Radionuclide | Carrier | Physical half-life, days | βmax, MeV | βmean, MeV | Mean rangec in tissue, mm | γ-Energy, keV (%) |
|---|---|---|---|---|---|---|
| 89Sr | chloride | 50.5 | 1.46 | 0.583 | 6.7 | – |
| 153Sm | EDTMP | 1.95 | 0.8 | 0.224 | 3.4 | 103 (28) |
| 32Pa | phosphate | 14.28 | 1.71 | 0.695 | 7.9 | – |
| 188Reb | HEDP | 0.71 | 2.12 | 0.76 | 11.0 | 155 (1) |
| 117mSnb | DTPA | 13.6 | no beta-emission | 0.3 | CE 159 | |
| 33Pb | phosphate | 25.34 | 0.249 | 0.85 | 0.05 | |
| 223Rab | chloride | 11.4 | alpha-emitter (eff. energy 26.4 MeV) | < 100 µm |
a
Not approved in Germany.
b
Clinical trial only.
c
Mean range in periosseous soft tissue.
EDTMP = Ethylenediaminotetramethylenephosphonate, HEDP = hydroxyethylenediphosphonate, DTPA = diethylenetriaminopentaacetate, CE = conversion electrons.